People · Operator
Named in public records as an officer, director or promoter · active 2010–2016 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Pathway Therapeutics, Inc. | — | Biotechnology | Series A | $16.9M | $14.5M | 2010 |
| Revitope Oncology, Inc. | — | Biotechnology | Series A | $13.4M | $296.4M | 2016 |
Julie Cherrington at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Julie Cherrington on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Mark Perry | 1 | 6 |
| Paul Goddard | 1 | 4 |
| Andrew Allen | 1 | 4 |
| Joshua Funder | 1 | 3 |
| Mark Harvey | 1 | 3 |
| Will Charles | 1 | 2 |
| Mark Cobbold | 1 | 2 |
| Raj Mehta | 1 | 2 |
| Hilary Lewis | 1 | 1 |
| Peter Joost | 1 | 1 |
| Carrie Hillyard | 1 | 1 |
| Hillary Lewis | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.